To print: Select File and then Print from your browser's menu

Title: Rosuvastatin Appears Safe and Effective for Treating Hyperlipidemia in Diabetic Patients with Chronic Kidney Disease: Presented at ASN

"Rosuvastatin Appears Safe and Effective for Treating Hyperlipidemia in Diabetic Patients with Chronic Kidney Disease: Presented at ASN"

By Maria Bishop PHILADELPHIA, PA -- November 11, 2005 -- Rosuvastatin appears to have a favorable effect on the atherogenic lipid profiles and high-sensitivity C-reactive protein (CRP) levels of hyperlipidemic diabetics with chronic kidney disease. These findings, from a 20-week randomized, open label trial, were reported here on November 10[^th at the 38^th Annual Meeting and Scientific Exposition of the American Society of Nephrology (ASN).

Diabetic patients with chronic kidney disease are at an increased risk for atherosclerosis because of dyslipidemia and a proinflammatory state as well as declining renal function, explained lead author Anil Verma, MD, Attending Physician, Department of Medicine, Candler Internal Medicine, Statesboro, Georgia, United States.

Rosuvastatin is known to improve dyslipidemia and to reduce inflammatory markers in the general population, he added.

Dr. Verma and colleagues enrolled 42 patients with type 2 diabetes and hyperlipidemic chronic kidney disease. Twenty-two patients were randomized to for 20 weeks of treatment with rosuvastatin 10 mg/day, while 20 patients were randomized to no treatment.

At baseline and on study completion researchers evaluated outcome measures using identical procedures in both treatment groups. Safety was assessed by clinical and laboratory monitoring.

After 20 weeks, the treated patients had a 30% decrease in total cholesterol from baseline, compared to a 1.36% increase in total cholesterol in the control group.

Statistically significant effects were also observed on low-density lipoprotein (LDL) cholesterol, with a decrease of 47% with rosuvastatin compared to a 2% increase without treatment. High-sensitivity CRP decreased by 50% with rosuvastatin and increased by 3.5% without treatment.

Elevations in liver enzymes and creatine kinase levels were not clinically significant in this study, but this was due to the small sample size, Dr. Verma noted.

No detrimental effect on renal function was observed, he said.

[Presentation title: Effect of Rosuvastatin on Dyslipidemia, High Sensitivity-C Reactive Protein and Renal Function in Diabetic Patients with Chronic Kidney Disease. Abstract 958]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.